MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.

Raymond James Financial Inc. bought a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) during ...